1 / 4

Idiopathic Pulmonary Fibrosis - Drug Pipeline Analysis 2016

The Idiopathic Pulmonary Fibrosis Market is Forecast to Show High Growth until 2016

rgunnam
Download Presentation

Idiopathic Pulmonary Fibrosis - Drug Pipeline Analysis 2016

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Idiopathic Pulmonary Fibrosis - Drug Pipeline Analysis and Market Forecasts to 2016

  2. The Idiopathic Pulmonary Fibrosis Market is Forecast to Show High Growth until 2016 The global idiopathic pulmonary fibrosis (IPF) market was valued at $84m in 2009. It is expected to increase with a compound annual growth rate (CAGR) of 25.1% from $84m in 2009 to $348m by 2016. Earlier the IPF market was underserved due to a lack of approved products. In October 2008, the Japanese manufacturer Shionogi received approval for Pirespa in Japan. It is under regulatory review for approval in the US and the EU. The expected increase in sales is due to the expected approval of Pirespa in the US and the EU and also the expected launch of Tracleer and Letiaris. Growth in the IPF market is being driven by the sales of Pirespa, off-label drug use and the anticipated approval of Letiaris and Tracleer. Gilead’s Letiaris and Actelion’s Tracleer are the most anticipated molecules in the IPF market. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Idiopathic-Pulmonary-Fibrosis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&Title=Pharmaceuticals_and_Healthcare Competition in the Idiopathic Pulmonary Fibrosis Market is Weak GlobalData found that the current competition in the IPF market is weak due to the unavailability of products for treatment of the disease. There is only one product approved for the treatment of IPF. Shionogi’s Pirespa got approved in 2008 in Japan for the treatment of IPF. Prior to the approval of Pirespa, the market had no approved products. The market was dominated by the off-label use of corticosteroids and immunosuppresants. The minimal efficacy and safety of off-label drugs and the poor response rates exhibited by patients demonstrate the huge unmet need existing in the market. Strong Late Stage Pipeline for Idiopathic Pulmonary Fibrosis GlobalData has found that there are over 40 molecules in the various stages of the pipeline. Tracleer and Letiaris are some of the late stage pipeline molecules. Enbrel and Veldona in Phase II are also showing promising activity in treating IPF.

  3. These pipeline molecules differ in their targets of action from the existing therapies. All these molecules are already approved for other indications and are in clinical trials for IPF. Tracleer and Letiaris are approved for pulmonary arterial hypertension. Enbrel is already an approved biologic for other indications. Hence, the probable approval of these molecules shows that there is a strong pipeline for IPF. However, IPF is an orphan disease and all these drugs in the pipeline have orphan drug status. Thus, the launch of potential molecules can be expected in the near future. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Idiopathic-Pulmonary-Fibrosis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&Title=Pharmaceuticals_and_Healthcare Weak Current Market Leads to Low Patient Compliance and Physician Satisfaction GlobalData has found that there is a lack of available treatment options in the IPF market. There is no approved drug available to IPF patients outside Japan. The market has only off-label drugs as pharmacological therapy for patients. A poor response rate and minimal safety and efficacy has led to low patient compliance and physican satisfaction towards these treatments. Although it has fewer survival benefits than the other treatments, lung transplantation appears to be the only option available for patients with end-stage idiopathic pulmonary fibrosis. Thus, the lack of available options has led to a weak market. GlobalData’s report, “Idiopathic Pulmonary Fibrosis - Drug Pipeline Analysis and Market Forecasts to 2016”, is an essential source of information and analysis on the global idiopathic pulmonary fibrosis (IPF) market. The report identifies the key trends shaping and driving the global IPF market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to significantly alter the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global IPF sector.

  4. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Idiopathic-Pulmonary-Fibrosis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&Title=Pharmaceuticals_and_Healthcare Or visit our report store: http://www.globaldata.com/reportstore Contact Information: Rajesh Gunnam rgunnam@globaldata.com +914066166782

More Related